Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002195 · ClinicalTrials.gov registry record · Phase 3
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT00002195 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 290 participants.
The verdict
NCT00002195, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002195
The ClinicalTrials.gov registry entry for NCT00002195 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002195 about?
NCT00002195 is a clinical study titled "A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
What is the current status of trial NCT00002195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants.
What interventions are being tested in trial NCT00002195?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002195?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.